Prostate Cancer International is
for 2011 by Great NonProfits
According to a media release issued yesterday by Dendreon, the company now expects to submit a revised New Drug Application for sipuleucel-T (Provenge) to the US Food and Drug Administration (FDA) in November this year.
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Leave a Comment »
Today’s news reports address items on: The burden of prostate cancer in Canada Pelvic lymph node dissection and RALP Data from early trials of sipuleucel-T in advanced prostate cancer Implementation of osteoporosis screening guidelines in prostate cancer patients
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Canada, guidelines, incidence, mortality, osteoporesis, pelvic lymph node dissection, PLND, Provenge, screening, sipuleucel-T | 3 Comments »
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer.
Filed under: Drugs in development | Tagged: androgen-independent prostate cancer, Dendreon, Provenge, sipuleucel-T | 2 Comments »
According to a media release from Dendreon earlier this evening, there will be a conference call at 9 am EST/6 am PT tomorrow morning (Tuesday, April 14) at which the company will “review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE® [...]
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Comments Off
The “New” Prostate Cancer InfoLink has seen a couple of statements from members of the financial community in the last few days that could mislead the unwary into believing that Dendreon’s investigational immunotherapeutic agent, sipuleucel-T (Provenge), has already demonstrated a statistically significant survival benefit in its most recent Phase III clinical trial (the IMPACT trial)
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site